Althea Technologies has been awarded a contract from Altus Pharmaceuticals to produce its ALTU-238 product candidate, a crystallized formulation of Human Growth Hormone (HGH) that is designed to be administered once-weekly through a fine gauge needle for the treatment of HGH disorders. “Althea Technologies is a seasoned CMO with significant experience in the manufacture of recombinant proteins,” said Sheldon Berkle, president and chief executive officer of Altus. “We lo...